JBIO's Quality Score fell 1 point on Fri, Oct 30, to -5. Made no higher high and higher low.
Follow JBIO's trial news. Pro members can get an alert when Jade Biosciences files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 27% in 3 months while the S&P 500 was flat.
−2Dilution
| Holding it back | 114.7% more shares than a year ago |
| Latest filing | 10-Q, Aug 10 |
After its last 4 reports it closed +4.3% on average, higher 3 of 4 times.
The company says its cash lasts into 1H 2028 (8-K, Jun 1).
No open-market buys or sales by its officers or directors in their filings of the last year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
JBIO is #207 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 207 |
Expected to report Thu Nov 12, before the open (in 10 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 10, 2026 | -0.2% | -1.1% | +12.5% |
| May 7, 2026 | -1.6% | +6.6% | -0.4% |
| Mar 6, 2026 | -3.2% | +1.2% | -0.1% |
Officers and directors with a Form 4 in the last 12 months.
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
JBIO scores -5 today, which Breakaway calls Poor. It is #207 of 291 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 27% in 3 months while the S&P 500 was flat. Shares: 2.1 times the count a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
JBIO scores -5 today, which Breakaway calls Poor (below zero). That is #207 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind JBIO's -5.
Expected to report Thu Nov 12, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. JBIO closed higher after 3 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.